Login to Your Account

Sunesis setback: FDA wants more data on AML drug

By Michael Fitzhugh
Staff Writer

Friday, July 24, 2015

With the FDA telling Sunesis Pharmaceuticals Inc. it wants additional clinical evidence on the experimental AML drug Qinprezo before backing submission of a new drug application, the company said it will "evaluate and refine" its U.S. plans while pursuing marketing approval for the drug in Europe.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription